Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 · kind B2 · utility
12Cited by
22References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 14, 2003 |
| Grant date | Mar 10, 2009 |
| Priority date | — |
| Expiry date | Jul 9, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D498/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
This invention concerns quinazoline analogs of Formula I:where an A group is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to three independent R3 groups. The invention also includes methods of using these compounds as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.